

PHARMACEUTICAL 2023

Anebulo Pharmaceuticals Inc. Rank 57 of 446







RealRate

## Anebulo Pharmaceuticals Inc. Rank 57 of 446

The relative strengths and weaknesses of Anebulo Pharmaceuticals Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Anebulo Pharmaceuticals Inc. compared to the market average is the variable Other Assets, increasing the Economic Capital Ratio by 966% points. The greatest weakness of Anebulo Pharmaceuticals Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 34% points.

The company's Economic Capital Ratio, given in the ranking table, is 237%, being 194% points above the market average of 43%.

Input Variable	Value in 1000 USD
Assets, Current	0
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	381
Liabilities, Non-Current	0
Other Assets	15,579
Other Compr. Net Income	0
Other Expenses	0
Other Liabilities	132
Other Net Income	5.6
Other Revenues	0
Property and Equipment	0
Research and Development	2,962
Selling, General and Administrative Expense	3,870

Output Variable	Value in 1000 USD
Assets	15,579
Liabilities	513
Expenses	6,831
Revenues	0
Stockholders Equity	15,067
Net Income	-6,826
Comprehensive Net Income	-6,826
Economic Capital Ratio	237%

